IVA - Inventiva Sino Biopharm sign licensing pact to develop commercialize NASH treatment

• France-based clinical-stage biopharma Inventiva ( NASDAQ: IVA ) on Wednesday said it had entered into a licensing and collaboration agreement with a unit of Chinese pharmaceutical group Sino Biopharm for its non-alcoholic steatohepatitis (NASH) treatment lanifibranor.
• As per the deal, Inventiva ( IVA ) will get a $12M upfront payment along with $5M in short term potential milestone payments.
• IVA will also be eligible to get up to $290M in clinical, regulatory and commercial milestone payments, in addition to tiered royalties.
• Sino Biopharm will oversee the development and commercialization of lanifibranor in Greater China, IVA said in a statement .
• IVA's lanifibranor had previously received a breakthrough therapy designation from the U.S. FDA.
• U.S.-listed shares of IVA -2.8% to $3.82 after hours.

For further details see: